What is the therapeutic effect of 6 courses of gaffetuzumab?

Glofitumab uses periodic intravenous infusion to treat relapsed or refractory non-Hodgkin lymphoma. It is generally infused every three weeks, and the entire treatment course is up to 12 cycles. According to currently disclosed overseas clinical research data, patients often see significant effects within the first 6 courses of treatment (i.e., the first 18 weeks). In particular, some patients can achieve partial or complete remission in imaging and clinical indicators after the third or fourth cycle.

The reason why this drug can exert rapid effects in a short period of time is closely related to its unique dual-target mechanism. It activates the immune response in the body by bridging T cells and tumor B cells, and can continuously trigger T cell-mediated tumor killing effects. Especially in malignant tumors such as DLBCL where the TME (tumor microenvironment) is significantly immunosuppressed, gaffetuzumab has positive significance in activating "cold" tumors.

Most patients can know whether they have achieved treatment response at the 6th cycle. Therefore, this stage is regarded as an important time point for efficacy evaluation. If some patients have achieved complete remission (CR) at this stage, they may consider terminating treatment early or transitioning to the observation period. For those who fail to achieve the expected results, it may be considered to extend to 12 cycles or even be evaluated in combination with other treatment strategies (such as radiotherapy, CAR-T).

It is worth mentioning that although gratinumab is an immune-activating drug, its safety is controllable. Through the "dose escalation + pretreatment" model (obatinuzumab pretreatment can reduce the risk of initial cytokine release), the incidence of immune-related adverse events is significantly reduced. Reactions such as CRS, fever, and fatigue are mostly mild to moderate and can be relieved with supportive treatment or slowing down the infusion rate, and rarely require permanent discontinuation of the drug.

To sum up, the effect evaluation value of gaffetuzumab after 6 cycles is high, and some patients can obtain significant relief in the short term. It is a fast, convenient and efficient new immunotherapy option for patients who have failed traditional treatments.

Reference materials:https://www.drugs.com/glofitamab.html